Translational Bytes

Nov18 YourPGx: Empowering Patients with Your PGx

After decades of discovery and translational research into genetic determinants of loss of efficacy and increased toxicity, the pharmacogenetics (PGx) field has set its eyes on implementation of important findings. Groups such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) have p...

Oct29 Star Trek: Tissue Chips in Space

“That’s one small step for a man, one giant leap for mankind." — Neil Armstrong It’s been 50 years since we landed on the moon, and technologic innovation – both in space and on earth – has bounded forward. One of those technology innovations has been microphysiological systems, or “organs-on-c...

In a recent Commentary published in Clinical and Translational Science ( CTS ), Dr. Peter Marks, the Director of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), provides a clear and compelling overview of the FDA's flexible regulatory app...

There is much debate among parents, educators, and employers about the appropriate amount of screen time. In fact, most families and schools have developed rules surrounding the use of social media and electronic communication apps with the intent of preserving the human interactions that are so cr...

Sep16 Dishing Out the QT Risk

Early identification of QT-prolongation or pro-arrhythmic risk for drugs in development has historically relied on binding or functional assays for hERG and other ion channels, with follow-up studies in animals. This hERG-to-animal approach entails a jump from simple and relatively uncertain to cos...

Historically, cancer detection and drug response monitoring required collecting tumor biopsies, which can be a very invasive procedure, to characterize many types of solid tumors such as non-small cell lung cancer (NSCLC), and is practically infeasible for many others. Furthermore, given their inva...

A recent publication in CTS by Lyauk et al . presents results from an evaluation of dose selection in NDAs approved by the FDA between 2015 and 2017, in an effort to characterize the extent to which sponsors follow the “learn and confirm” paradigm of dose selection.

The most recent impact factor (IF) numbers are in, and Clinical and Translational Science (CTS) has again doubled its IF to 3.989. The 2018 IF is the first year that we “own” the entire metric. Last year, we owned half the 2017 metric and the IF was 1.954, while two years ago, the old editori...

Jul12 The Difference Is Night and Day

Does your study call for recurrent measurement of heart rate or blood pressure? If so, read “ Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and QT Interval for Healthy Subjects Who Received Placebo in Phase I Trials ” by Mukul Minocha et al . In this creative appr...

Page:

of 9